A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled multi-center study
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Muromonab CD3 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 26 Mar 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 23 Mar 2012 Additional locations identified as reported by as reported by European Clinical Trials Database.